



Immediate deamination from the aminomethyl group attached to 1,2-dihydropyrazin-2-one derivative during catalytic hydrogenation

Yoshio Okada,^{a,b,*} Yutaka Fujisawa,^a Akihisa Morishita,^a Kimitaka Shiotani,^a Anna Miyazaki,^a Yoshio Fujita,^a Tingyou Li,^b Yuko Tsuda,^{a,b} Toshio Yokoi,^{a,b} Sharon D. Bryant^c and Lawrence H. Lazarus^c

^aFaculty of Pharmaceutical Sciences, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan

^bHigh Technology Research Center, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan

^cPeptide Neurochemistry, LCBRA, National Institute of Environmental Health Science, Research Triangle Park, NC 27709, USA

Received 28 June 2002; revised 2 September 2002; accepted 6 September 2002

Abstract—The catalytic hydrogenation of 3,6-bis(benzyloxycarbonylaminoethyl)-5-methyl-1,2-dihydropyrazin-2-one to remove benzyloxycarbonyl (Z) groups resulted in a side reaction. Purification by reverse-phase HPLC and analysis by proton nuclear magnetic resonance (¹H NMR) spectroscopy identified the product as 3-aminomethyl-5,6-dimethyl-1,2-dihydropyrazin-2-one. It was determined through the synthesis of two 1,2-dihydropyrazin-2-one derivatives, composed of alanine and 2,3-diaminopropionic acid that deamination occurred specifically and easily (under atmospheric pressure and at the room temperature) only in the case of 6-benzyloxycarbonylaminoethyl-3,5-dimethyl-1,2-dihydropyrazin-2-one. The catalytic hydrogenation of 3,6-bis(benzyloxycarbonylaminoethyl)-5-methyl-1,2-dihydropyrazin-2-one specifically yields the deaminated product, 3-aminomethyl-5,6-dimethyl-1,2-dihydropyrazin-2-one. © 2002 Elsevier Science Ltd. All rights reserved.

The opioid mimetic, 3,6-bis(4'-tyrosylaminobutyl)-5-methyl-1,2-dihydropyrazin-2-one exhibited moderate binding activity to μ -opioid receptors.¹ In order to synthesize more potent and selective μ -opioid agonists and to study structure–activity relationships, additional Z-protected 1,2-dihydropyrazin-2-one derivatives (Scheme 1; **I–IV**) were prepared to be used as synthetic intermediates.

Four 1,2-dihydropyrazin-2-one derivatives (**I–IV**) containing one to four methylene linkers were prepared (Scheme 1).^{1–3} The Boc group of the protected dipeptidyl chloromethyl ketone was removed with HCl-dioxane, and the resulting peptidyl chloromethyl ketone hydrochloride salt was refluxed in either acetonitrile or methanol to form the 1,2-dihydropyrazin-2-one ring. The Z-protected derivative was hydrogenated over a Pd catalyst in 50% acetic acid to remove the Z groups. Although hydrogenation of three derivatives (**I–III**) gave the corresponding desired products (**Ia–IIIa**), hydrogenation of compound **IV** produced an unexpected product (**V**) instead of **IVa** during the final step.

MALDI-TOF mass spectrometry (MS) was utilized to investigate the side reaction that occurred during the hydrogenation step in the removal of the Z groups. Compounds (**I–IV**) were hydrogenated and the products were analyzed by MS as a function of time (10, 20, 30, 60 min). Hydrogenation of compounds **I–III** yielded the desired synthetic product (**Ia–IIIa**) within 10 minutes and deprotection was completed within 60 minutes. In contrast, the reaction for compound **IV** yielded both the desired (**IVa**) and unexpected products (**V**) within the first 10 minutes and after 60 minutes all of compound **IV** was transformed into the unexpected product (**V**), which had the molecular weight of 153.


This new and unexpected product (**V**) was purified by reverse-phase HPLC and identified by proton nuclear magnetic resonance (¹H NMR) spectroscopy in pyridine-*d*₅. The desired product was anticipated to contain two aminomethyl groups and one methyl group, whereas NMR results indicated that the product had one aminomethyl group and two methyl groups [δ ppm (400MHz): 4.87 (2H, s, methylene of aminomethyl group), 2.23 (3H, s, methyl), 2.15 (3H, s, methyl)]. In addition, the molecular weight of the unexpected product (153) was smaller than that of the desired

* Corresponding author. E-mail: okada@pharm.kobegakuin.ac.jp


product (**IVa**) (168). The presence of only one aminomethyl group could be explained by deamination of the aminomethyl moiety attached to the 1,2-dihydropyrazin-2-one ring at either position 3 or 6.

To determine from which position the amino group was removed, two 1,2-dihydropyrazin-2-one derivatives, composed of alanine and 2,3-diaminopropionic acid, were prepared (Scheme 2).

Compounds **VI** and **VII** were hydrogenated as stated above, and the reaction mixture was analyzed by MS as



Scheme 1. Reagents and conditions: (i) HCl–dioxane; (ii) reflux in either methanol or acetonitrile; (iii) H_2/Pd in 50% acetic acid.



Scheme 2. Reagents and conditions: (i) HCl–dioxane; (ii) reflux in methanol; (iii) H_2/Pd , 50% acetic acid.

a function of time (10, 20, 30 min, and 1, 2, 4 and 6 h). Both deprotected products **VIII** and **IX** obtained during hydrogenation should have the same molecular weight, 153.20; however, the deaminated form (**X**) which had a molecular weight of 138.17, was detected at 20 min and the entire compound **IX** was transformed after 6 h reaction time.

Purification by reverse-phase HPLC and ^1H NMR analysis of compound **VIII** in pyridine- d_5 revealed that the catalytic hydrogenation of compound **VI** produced 3-aminomethyl-5,6-dimethyl-1,2-dihydropyrazin-2-one [δ : ppm 4.87 (2H, s, 3- CH_2NH_2); 2.22 (3H, s, 5- or 6- CH_3); 2.15 (3H, s, 5- or 6- CH_3)]. Similar analyses of compound **X** revealed that catalytic hydrogenation of compound **VII** yielded 3,5,6-trimethyl-1,2-dihydropyrazin-2-one; the deaminated product [δ : ppm 2.60, 2.24, 2.15 (3H \times 3, s, 3- or 5- or 6- CH_3)].

These data confirm that deamination occurred specifically at position 6 of the 1,2-dihydropyrazin-2-one ring only in the case of compound **VII**. In addition, it demonstrated that catalytic hydrogenation of compound **IV** specifically gave the deaminated product, 3-aminomethyl-5,6-dimethyl-2(1*H*)-1,2-dihydropyrazin-2-one. Furthermore, the time of deamination was shorter for compound **IV** (60 min) relative to compound **VII** (6 h). The dissimilar reaction kinetics may have resulted from the different partial electron densities or differences in the dimensional structure of the starting material (Schemes 1 and 2).

Interestingly, our group reported previously that catalytic hydrogenation of the compounds 6-benzyl-3-benzyloxycarbonylmethyl-5-methyl-1,2-dihydropyrazin-2-one (**A**) and 3-benzyl-6-benzyloxycarbonylmethyl-5-methyl-1,2-dihydropyrazin-2-one (**B**) specifically produced the decarboxylated 6-benzyl-3,5-dimethyl-1,2-dihydropyrazin-2-one due to low electron density of methylene moiety at position 3 on the 1,2-dihydropyrazin-2-one ring.⁴ Decarboxylation was specifically observed at position 3 on the 1,2-dihydropyrazin-2-one ring. These differences allowed us to presume that deamination and decarboxylation were caused by different mechanisms. Deamination would occur owing to the location of an amino group at a similar position to benzyl or allyl,^{5–10} rather than owing to low electron density. It can be deduced that the property of C–N bond at position 6 is similar to that of a benzylic or allylic C–N bond, while the property of the C–N bond at position 3 is quite different from that of benzylic or allylic C–N bond.

It is interesting that deamination of an aminomethyl moiety attached to 6 position of 1,2-dihydropyrazin-2-one derivative occurred easily at room temperature under atmospheric pressure, although reactivity of deamination from benzylamine derivatives are very low.^{5,6,11} This high reactivity in the present report might be attributable to the low electron density of C–N bond compared with benzylamine or relatively high affinity of 1,2-dihydropyrazin-2-one moiety for the palladium

catalyst. We suggested that 1,2-dihydropyrazin-2-one 6-methyl-group can be a candidate for novel benzyl type amino protecting group removable by catalytic hydrogenolysis at ordinary temperature and pressure.

Acknowledgements

This work was supported in part by a Grant-in-Aid for Kobe Gakuin University Joint Research (B).

References

1. Okada, Y.; Fukumizu, A.; Takahashi, M.; Yamazaki, J.; Yokoi, T.; Tsuda, Y.; Bryant, S. D.; Lazarus, L. H. *Tetrahedron* **1999**, *55*, 14391–14406.
2. Taguchi, H.; Yokoi, T.; Tsukatani, M.; Okada, Y. *Tetrahedron* **1995**, *51*, 7361–7372.
3. Okada, Y.; Tsukatani, M.; Taguchi, H.; Yokoi, T.; Bryant, S. D.; Lazarus, L. H. *Chem. Pharm. Bull.* **1998**, *46*, 1372–1382.
4. Taguchi, H.; Yokoi, T.; Okada, Y. *Chem. Pharm. Bull.* **1996**, *44*, 2037–2041.
5. Velluz, L.; Amiard, G.; Heyness, R. *Bull. Soc. Chim. Fr.* **1954**, 1012–1015.
6. Velluz, L.; Anatol, J.; Amiard, G. *Bull. Soc. Chim. Fr.* **1954**, 1449–1454.
7. Murchú, C. *Tetrahedron Lett.* **1969**, *38*, 3231–3234.
8. Dahn, H.; Garbarino, J. A.; O'Murchu, C. *Helv. Chim. Acta* **1970**, *53*, 1370–1378.
9. Mitui, S.; Sugi, Y. *Tetrahedron Lett.* **1969**, *16*, 1287–1969.
10. House, H. O. In *Modern Synthetic Reactions*; 2nd ed.; Breslow, R., Ed.; Catalytic hydrogenation and dehydrogenation; W. A. Benjamin: California, 1972; pp. 1–34.
11. Haas, H. J. *Chem. Ber.* **1961**, *94*, 2442–2446.